FDA tells Sprout Pharma, like it or not the black box on Addyi stays, but we will dilute the warning
When the controversial first drug for low sexual desire in women was finally granted approval in 2015, critics accused the FDA of bowing to pressure …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
